KCR has opened new offices in London and Berlin, and is now turning its attention to France.
KCR, the CRO operating in 18 countries in Europe as well as the US, has opened new offices in London and Berlin, and is now turning its attention to France.
“I am very excited seeing KCR strengthening its visibility across Western Europe, particularly in the UK and Germany, where we have already been enjoying partnerships with locally based or represented companies,” says Mike Jagielski, CEO of KCR. “Having our own entities registered in these countries will make our collaboration even stronger. It will also equip KCR with local law benefits and make our business cooperation easier. The next country we will aim for is France.”
KCR has operated in Central and Eastern Europe and the Commonwealth of Independent States since 1997. Having a local team in each of the offices gives the company insight into local regulations, and has also helped to build extensive relationships with key opinion leaders and principal investigators, according to the CRO.
KCR offers three types of professional contract research services: clinical development services, functional service provision and post-marketing clinical services, in a wide spectrum of therapeutic areas.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.